Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Revive Therapeutics Ltd (RVV.CN)

Revive Therapeutics Ltd (RVV.CN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 132,202
  • Shares Outstanding, K 259,220
  • Annual Sales, $ 0 K
  • Annual Income, $ -5,382 K
  • 60-Month Beta 0.02
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 13.41
Trade RVV.CN with:
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm -0.07
  • Most Recent Earnings -0.01 on 12/31/20
  • Next Earnings Date N/A
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

    TSX Drug Specialty & Generic

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.430 +18.60%
on 03/25/21
0.570 -10.53%
on 03/10/21
-0.030 (-5.56%)
since 03/09/21
3-Month
0.330 +54.55%
on 03/05/21
0.760 -32.89%
on 02/16/21
-0.090 (-15.00%)
since 01/08/21
52-Week
0.110 +363.64%
on 04/20/20
0.920 -44.57%
on 12/14/20
+0.355 (+229.03%)
since 04/09/20

Most Recent Stories

More News
Revive Provides Dial-In Information for Annual and Special Meeting

Revive Therapeutics Ltd. ("Revive" or the "Company") (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders,...

RVV.CN : 0.510 (+5.15%)
RVVTF : 0.4050 (+3.98%)
Psychedelics Companies are Establishing Core IPs in Growing Market

, /PRNewswire/ -- The emerging psychedelics therapy market has been among the top financial stories of 2021 so far, driven by major legal and regulatory breakthroughs, promising research and groundbreaking...

PULL.CN : 0.500 (+1.01%)
PRXTF : 0.4000 (+0.48%)
FTRP.CN : 6.030 (+4.87%)
FTRPF : 4.8000 (+5.29%)
AIKI : 1.0300 (-4.63%)
RVV.CN : 0.510 (+5.15%)
RVVTF : 0.4050 (+3.98%)
CBDT.CN : 0.710 (-2.74%)
EPWCF : 0.5551 (-4.29%)
Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19

Revive Therapeutics Ltd. ("Revive" or the "Company") (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders,...

RVV.CN : 0.510 (+5.15%)
RVVTF : 0.4050 (+3.98%)
Proactive news headlines including Karora Resources, Bragg Gaming Group, Empower Clinics and Naturally Splendid Enterprises

- Karora Resources Inc (TSE:KRR) (OTCMKTS:KRRGF) (FRA:5RN1) posts record net earnings for 2020, beats annual all-in-sustaining-cost guidanceclick here

NSP.VN : 0.060 (unch)
KRRGF : 3.1900 (+2.90%)
NSP : 86.46 (+0.83%)
NSPDF : 0.0516 (+3.20%)
BRGGF : 1.6700 (-2.91%)
VR.CN : 0.095 (-5.00%)
VRCFF : 0.0722 (-7.44%)
CBDT.CN : 0.710 (-2.74%)
EPWCF : 0.5551 (-4.29%)
RVV.CN : 0.510 (+5.15%)
RVVTF : 0.4050 (+3.98%)
CNI.CN : 2.090 (unch)
CLGUF : 1.6518 (-0.47%)
FG : 8.39 (+0.60%)
FGLDF : 0.0665 (-3.48%)
KULR : 2.4100 (-3.98%)
Revive Therapeutics Announces Successful Research Results for Psilocybin to Treat Traumatic Brain Injury and Filing of International Patent Application

Revive Therapeutics Ltd. ("Revive" or the "Company") (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders,...

RVV.CN : 0.510 (+5.15%)
RVVTF : 0.4050 (+3.98%)
Why Canada is Becoming a Hub for Psychedelics Research and Development

, /PRNewswire/ -- has become home to some of the most important research and development happening today in the mental health and wellness space. Psychedelic therapy emerged as a breakthrough mental...

NUMI.VN : 1.040 (-0.95%)
LKYSF : 0.8250 (-1.79%)
CBDT.CN : 0.710 (-2.74%)
EPWCF : 0.5551 (-4.29%)
RVV.CN : 0.510 (+5.15%)
RVVTF : 0.4050 (+3.98%)
LITT.VN : 0.075 (+7.14%)
RMANF : 0.0458 (-23.67%)
AIKI : 1.0300 (-4.63%)
With Recent Advancements, North America Is Expected To Dominate Psychedelic Drugs Market

, /PRNewswire/ -- The time of "Tune In… Turn On… and Dropout" psychedelics, such as certain, mushrooms and of course, LSD were not only not legal, but no researcher could even suggest studying the...

MCUR.CN : 0.470 (+6.82%)
MCURF : 0.3750 (+6.02%)
MMEDF : 2.6900 (+3.07%)
FTRP.CN : 6.030 (+4.87%)
FTRPF : 4.8000 (+5.29%)
CLXPF : 1.3400 (+1.52%)
RVV.CN : 0.510 (+5.15%)
RVVTF : 0.4050 (+3.98%)
Global Behavioral Health Market Where Psychedelics Have Shown Tremendous Potential Could Hit $240 Billion By 2026

, /PRNewswire/ -- Many people and investors may be confused, thinking that the Psychedelics market is part of the cannabis market. It is not a way to get higher 'highs' in the legal cannabis market…...

MCUR.CN : 0.470 (+6.82%)
CLXPF : 1.3400 (+1.52%)
MCURF : 0.3750 (+6.02%)
CMPS : 35.80 (-3.66%)
FTRP.CN : 6.030 (+4.87%)
FTRPF : 4.8000 (+5.29%)
RVV.CN : 0.510 (+5.15%)
RVVTF : 0.4050 (+3.98%)
PHRM.CN : 0.250 (+25.00%)
PHRRF : 0.2155 (+38.85%)
Proactive news headlines including Mandalay Resources Corporation, Loop Insights, Nano One Materials and Delta 9 Cannabis

- Mandalay Resources Corporation (TSE:MND) (OTCQB:MNDJF) (FRA:R7X2) says 2020 results underline sustainability of its turnaround last year click here

N.VN : 0.275 (unch)
MNDJF : 1.5900 (-4.22%)
N : 90.34 (unch)
NXTTF : 0.2217 (+0.36%)
VRNDF : 0.4125 (+3.80%)
MTRX : 13.40 (unch)
RACMF : 1.3900 (+4.12%)
AAGFF : 0.7200 (-2.70%)
EDV.TO : 27.72 (-0.96%)
EDVMF : 22.1100 (-0.76%)
NC.CN : 0.830 (+5.06%)
NTTCF : 0.6613 (+4.97%)
NSP : 86.46 (+0.83%)
NSPDF : 0.0516 (+3.20%)
RVV.CN : 0.510 (+5.15%)
RVVTF : 0.4050 (+3.98%)
BYRN.CN : 1.600 (+4.58%)
BYRN : 1.2600 (+4.13%)
VLNCF : 2.0926 (-0.82%)
UPDATE -- Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19 with Planned Completion and Emergency Use Authorization Request

Revive Therapeutics Ltd. ("Revive" or the "Company") (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders,...

RVV.CN : 0.510 (+5.15%)
RVVTF : 0.4050 (+3.98%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Key Turning Points

3rd Resistance Point 0.537
2nd Resistance Point 0.523
1st Resistance Point 0.517
Last Price 0.510
1st Support Level 0.497
2nd Support Level 0.483
3rd Support Level 0.477

See More

52-Week High 0.920
Fibonacci 61.8% 0.611
Fibonacci 50% 0.515
Last Price 0.510
Fibonacci 38.2% 0.419
52-Week Low 0.110

See More

Business Summary

Revive Therapeutics Ltd is focused on the research, development, and commercialization of novel psychedelic and cannabinoid-based life sciences products and drug repurposing for infectious diseases. The firm's technology is being developed to fill the medical needs for diseases and disorders such as...

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar